Initially, nivolumab and pembrolizumab, which are anti-programmed cell death 1 (PD-1) antibodies, were effective as second-line therapies for patients with unresectable advanced or recurrent esophageal cancer [1,2]. Here, PDCD1 is linked to esophageal cancer.